Cancer Clinical Trials in Southwest Washington

Meningiomas
A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Any solid tumor with brain mets
A071701 Genomically-Guided Treatment Trial in Brain Metastases (from any solid tumor-Central screening for alteration in CDK pathway, P13K/AKT/mTOR pathway, and NTRK/ROS1 translocation.)

HER 2 neg-Met.
S1703 Serum Tumor marker Directed Disease Monitoring in patients with Hormone Receptor positive HER2 Negative Metastatic Breast Cancer

Triple Negative Stage I-III
A012103  OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

ER+, HER2-, low risk (oncotype <25, mamaprint low, or prosigna risk <40) _postmenopausal, tumor size <3cm N0.
A012301 LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Patients with Molecular Low-Risk Early-Stage Breast Cancer

ER +PR+ HER2- premenopausal Oncotype </=25.
BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER+, PR+, HER2- Breast Cancer and an Oncotype Recurrence Score </=25.  (Available only at PeaceHealth St. John, Longview)

Mammaprint Ultrahigh, HR+, HER2- stage II-III
S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Triple Negative T2-T4, N0, M0 or T1-T3, N1-2, M0
S2212 A Randomized Phase III study- Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (Scarlet)

Resected pancreatic
EA2192 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation

Refractory small bowel
S1922 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel vs. FOLFIRI in refractory small bowel adenocarcinoma

Metastatic pancreatic
S2001 Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib alone as maintenance Therapy in Metastatic Pancreatic Cancer patients with Germline BRCA1 or BRCA2 Mutations.

Pancreatic Neuroendocrine
S2104 Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High Risk Pancreatic Neuroendocrine Tumors

Stage IV HER2 neg. GE adeno
A022102 Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX with Nivolumab for first line treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

Metastatic BRCA1/2 or PALB2-associated Pancreatic cancer
A022106 Phase II/III second-line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma

S2303 Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Rare GU
A031702 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers

Prostate radiosurgery registry
NCT01226004 Multi-Institutional Registry for Prostate Cancer Radiosurgery  (Available only at PeaceHealth Southwest)

Urothelial Cancer
A032103 MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer

Post Prostatectomy prostate
EA8191 Phase III Study of Local or Systemic Therapy intensification directed in Prostate Cancer patients with Post Prostatectomy Biochemical Recurrence

Advance papillary Renal Cell
S2200 A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma

Neoadj high risk prostate 
S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations

Squamous Head/Neck
EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Head/Neck
RTOG 1216 Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High Risk Squamous Cell Cancer of the Head and Neck   (Available only at PeaceHealth St. John, Longview)

Advanced Nasopharyngeal that has progressed after treatment
A092105 Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with advanced Nasopharyngeal Carcinoma that have progressed after Platinum Treatment and Immunotherapy

Recurrent/second primary H&N squamous with high-risk features
EA3191 A Phase II Randomized trial of Adjuvant Therapy with Pembrolizumab after resection of Recurrent/second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

Recurrent or Metastatic H&N squamous cell-Platinum refractory
A092205 Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease

Sarcomatoid Mesothelioma  
A082101 Neoadjuvant Immunotherapy in Sarcomatoid mesothelioma

ALCHEMIST substudy resected NSCLC
A081801 Integration of Immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO

Met. Or recurrent NSCLC
LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (substudies: S1900A, S1900E)

Metastatic NSCLC EGFR
EA5182 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Stage IIIB-IV lung cancer-patients >70 years old
EA5221 A Randomized Phase III trial of Chemo-Immunotherapy vs Immunotherapy alone for the Vulnerable older adult with advanced Non-small cell lung cancer-The ACHIEVE study

Stage II-IIIb NSCLC after complete resection and pathologic CR to neoadj tx 
S2414 A Randomized Phase III Trial incorporating pathologic complete response in Participants with Early stage NSCLC to Optimize Immunotherapy in the adjuvant setting (INSIGHT)

CLL/SLL
S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly diagnosed Asymptomatic High-Risk patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia/Small Lymphocytic Lymphoma : EVOLVE CLL/SLL study

Older patients (age 70 or age 60-70 with comorbidities precluding autoSCT) mantle cell lymphoma
A052101 A Randomized Phase III trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as upfront treatment in Older Patients with Mantle Cell Lymphoma 

1L low tumor burden classic Follicular Lymphoma 
S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low tumor burden Follicular Lymphoma
 

Multiple Myeloma
S2209 A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or in a Subset of “Intermediate Fit” comparing Upfront Three Drug Induction Regimens Followed by Double or Single Agent maintenance

Smoldering Myeloma-diagnosed with asymptomatic high risk within past 12 months 
EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) 

Observation of immune checkpoint inhibitor toxicities
S2013 Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Cancer related fatigue-therapy complete
URCC-18007 Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue

Cancer related insomnia stage I-IV all cancer types on treatment
URCC-19185 Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

Stage IV non-small cell lungcancer (NSCLC), pancreatic adenocarcinoma, or colorectal cancer-plan to start first line in the next 6 weeks or has started first line in the previous 6 weeks.
URCC22063 LOTUS-CC: Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia